Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Inclusion Criteria:

* Diagnosis of multiple myeloma (MM)

  * Salmon-Durie stage IIA or IIIA
  * No stage B disease
* Meets ≥ 1 major AND 1 minor criterion OR ≥ 3 minor criteria

  * The following are considered major criteria:

    * Plasmacytoma on tissue biopsy
    * Bone marrow plasmacytosis with ≥ 30% plasma cells
    * Monoclonal paraprotein ≥ 3,500 mg/dL (IgG) or ≥ 2,000 mg/dL (IgA) OR monoclonal protein (Bence-Jones protein) ≥ 1,000 mg by 24-hour urine collection
  * The following are considered minor criteria:

    * Bone marrow plasmacytosis 10-29% of marrow cellularity
    * Monoclonal globulin spike \< 3,500 mg/dL (IgG) or \< 2,000 mg/dL (IgA)
    * Lytic bone lesions
    * Decrease in normal IgM (\< 50 mg/dL), IgA (\< 100 mg/dL), or IgG (\< 600 mg/dL)
* Disease progression after ≥ 1 prior systemic treatment regimen\* for MM (e.g., chemotherapy, high-dose corticosteroids, thalidomide, or bortezomib), defined as \> 25% increase in serum or urine M-protein
* No solitary plasmacytoma
* No non-secretory MM (absent serum or urinary M-protein)
* ECOG performance status 0-2
* Life expectancy \> 6 months
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 3 times ULN
* Creatinine ≤ 2.0 mg/dL
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Fasting cholesterol ≤ 350 mg/dL
* Fasting triglycerides ≤ 400 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective double-method contraception
* Must agree not to donate blood, sperm, or ova during and for 4 weeks after completion of study treatment
* No other prior or concurrent malignancy or myelodysplasia except for the following:

  * Basal cell or squamous cell skin cancer
  * Carcinoma in situ of the cervix
  * Localized cancer treated with surgery only with no evidence of disease for \> 5 years
* No history of recurrent deep vein thrombosis (DVT)/pulmonary embolism (PE) or DVT/PE occurring while on therapeutic levels of anticoagulation

  * Patients with DVT/PE within the past 6 months are eligible provided they receive full anticoagulation during study treatment
* No active infection requiring oral or intravenous antibiotics
* No uncontrolled illness including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric illness or social situations that would preclude study compliance
* No known hepatitis B or C
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide or CCI-779
* See Disease Characteristics
* Prior lenalidomide allowed
* Prior high-dose chemotherapy with stem cell transplantation allowed
* More than 4 weeks since prior chemotherapy or other antimyeloma systemic therapy (e.g., thalidomide, bortezomib, or high-dose corticosteroids) and recovered
* No prior exposure to both lenalidomide and mTOR inhibitors (given together)

  * Treatment with single-agent lenalidomide or single-agent mTOR inhibitor allowed
* No other concurrent investigational agents
* No concurrent corticosteroids unless for physiologic maintenance
* No concurrent antiretroviral therapy for HIV-positive patients
* No concurrent myeloid growth factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])
* No concurrent grapefruit or grapefruit juice